| COGENCY-GLOBAL-INC |
COGENCY-GLOBAL-INC |
62%
|
ially owns more than 5% of our ordinary shares. 59 CORPORATE INFORMATION Jyong Biotech Ltd. was incorporated on January 26, 2018 as an exempted company limited by shares under the laws of Cayman Isla… |
| CORPORATE-INFORMATION-JYONG-BIOTECH-LTD |
CORPORATE-INFORMATION-JYONG-BIOTECH-LTD |
62%
|
ially owns more than 5% of our ordinary shares. 59 CORPORATE INFORMATION Jyong Biotech Ltd. was incorporated on January 26, 2018 as an exempted company limited by shares under the laws of Cayman Isla… |
| EXPIRATION-DATE-PHARMACEUTICAL-MANUFACTURING-LIC |
EXPIRATION-DATE-PHARMACEUTICAL-MANUFACTURING-LIC |
62%
|
API-1 and API-2 are similar and comparable, we will sign the Quality Agreement with this supplier for the raw materials for API-2. We will only be able to proceed with the Phase III PCP study after t… |
| HEALTH-EVER-BIO-TECH-CO-LTD |
HEALTH-EVER-BIO-TECH-CO-LTD |
62%
|
API-1 and API-2 are similar and comparable, we will sign the Quality Agreement with this supplier for the raw materials for API-2. We will only be able to proceed with the Phase III PCP study after t… |
| HONG-KONG-LIMITED |
HONG-KONG-LIMITED |
62%
|
that exceeds our coverage limitations or that is not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. In addition, if we cannot successfull… |
| INNOVATIVE-BIOTECH-CO-LTD |
INNOVATIVE-BIOTECH-CO-LTD |
62%
|
intellectual property-related claims; ● resources required to develop and implement policies and processes to promote ongoing compliance with applicable healthcare laws and regulations; ● costs requi… |
| LINKAGE-GLADDEN-ENTERPRISE-LTD |
LINKAGE-GLADDEN-ENTERPRISE-LTD |
62%
|
om Board of Governors of the Federal Reserve System: Balance sheet items, except for equity accounts December 31, 2025 RMB 6.9931 to $ 1 ; NTD31 .3700 to $ 1 December 31, 2024 RMB 7.2993 to $ 1 ; NTD… |
| MEDI-LIFE-CO-LIMITED |
MEDI-LIFE-CO-LIMITED |
62%
|
API-1 and API-2 are similar and comparable, we will sign the Quality Agreement with this supplier for the raw materials for API-2. We will only be able to proceed with the Phase III PCP study after t… |
| N-A-FACTORY-REGISTRATION-CERTIFICATE-HEALTH-EVER |
N-A-FACTORY-REGISTRATION-CERTIFICATE-HEALTH-EVER |
62%
|
API-1 and API-2 are similar and comparable, we will sign the Quality Agreement with this supplier for the raw materials for API-2. We will only be able to proceed with the Phase III PCP study after t… |
| NEW-PHARMACEUTICALS-COMPANY |
NEW-PHARMACEUTICALS-COMPANY |
62%
|
API-1 and API-2 are similar and comparable, we will sign the Quality Agreement with this supplier for the raw materials for API-2. We will only be able to proceed with the Phase III PCP study after t… |
| NOBEL-CONSUMER-CORPORATION |
NOBEL-CONSUMER-CORPORATION |
62%
|
ds of Jyong Biotech Ltd.’s initial public offering (the “IPO”) for (i) a possible settlement of the litigation with Taizhou Bay New District Administrative Committee, including the return of governme… |
| SIRA-VIEW-CORP |
SIRA-VIEW-CORP |
62%
|
API-1 and API-2 are similar and comparable, we will sign the Quality Agreement with this supplier for the raw materials for API-2. We will only be able to proceed with the Phase III PCP study after t… |
| TAIWAN-THE-TAIWAN-COMPANY |
TAIWAN-THE-TAIWAN-COMPANY |
62%
|
ices are not reported accurately. Additionally, the handling of any controlled substances must comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act. Drugs mu… |
| TOP-SHUNXING-BIO-TECH-CO-LIMITED |
TOP-SHUNXING-BIO-TECH-CO-LIMITED |
62%
|
that exceeds our coverage limitations or that is not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. In addition, if we cannot successfull… |
